StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.53+0.13 (+9.29%)

Close on Nov 13, 2026Market cap $11.00MP/E 1.1Yield –

Chemomab Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Chemomab Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2023 was $23.23M, up 143.7% year over year. For fiscal 2025 it was $5.83M, down 48.5% from the year before. The highest annual figure on record is $18.38M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.83M-48.5%
FY2024Dec 31, 2024$11.33M-38.4%
FY2023Dec 31, 2023$18.38M+8.3%
FY2022Dec 31, 2022$16.98M+168.0%
FY2021Dec 31, 2021$6.33M+35.2%
FY2020Dec 31, 2020$4.68M-64.8%
FY2019Dec 31, 2019$13.30M+77.0%
FY2018Dec 31, 2018$7.51M+20.6%
FY2017Dec 31, 2017$6.23M+161.3%
FY2016Dec 31, 2016$2.38M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.14M-83.4%
Q2 FY2025Jun 30, 2025$1.29M-78.2%
Q2 FY2024Jun 30, 2024$2.93M-46.0%
Q2 FY2023Jun 30, 2023$5.02M+72.3%
Q1 FY2023Mar 31, 2023$6.89M+150.9%
Q4 FY2022Dec 31, 2022$5.90M+147.4%
Q3 FY2022Sep 30, 2022$5.42M+264.7%
Q2 FY2022Jun 30, 2022$2.91M+123.0%
Q1 FY2022Mar 31, 2022$2.75M+137.3%
Q4 FY2021Dec 31, 2021$2.38M+90.0%
Q3 FY2021Sep 30, 2021$1.49M+44.2%
Q2 FY2021Jun 30, 2021$1.31M+54.3%
Q1 FY2021Mar 31, 2021$1.16M-25.5%
Q4 FY2020Dec 31, 2020$1.25M+22.1%
Q3 FY2020Sep 30, 2020$1.03M-81.5%
Q2 FY2020Jun 30, 2020$847.00K-67.1%
Q1 FY2020Mar 31, 2020$1.55M-62.5%
Q4 FY2019Dec 31, 2019$1.03M–
Q3 FY2019Sep 30, 2019$5.57M–
Q2 FY2019Jun 30, 2019$2.58M–
Q1 FY2019Mar 31, 2019$4.14M–

More Chemomab Therapeutics figures

See a number that looks wrong?